Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma
- 31 December 2010
- journal article
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 63 (6), 975-983
- https://doi.org/10.1016/j.jaad.2009.12.052
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Development of TLR9 agonists for cancer therapyJCI Insight, 2007
- Phase II Trial of a Toll-Like Receptor 9–Activating Oligonucleotide in Patients With Metastatic MelanomaJournal of Clinical Oncology, 2006
- A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoidesJournal of the American Academy of Dermatology, 2006
- Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Blood, 2006
- Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients With Previously Treated Non-Hodgkin LymphomaJournal of Immunotherapy, 2006
- Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cellsBlood, 2005
- Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15Blood, 2004
- Mycosis fungoides and the Sézary syndromeCurrent Opinion in Oncology, 2004
- Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphomaBlood, 2003
- Sézary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokinesBlood, 2002